Status:
COMPLETED
Effects of Arzoxifene on Bone Mass and the Uterus
Lead Sponsor:
Eli Lilly and Company
Conditions:
Postmenopausal Bone Loss
Eligibility:
FEMALE
45-60 years
Phase:
PHASE3
Brief Summary
The purposes of this study are to determine: * The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. * The effects of arzoxifene on the uterus (w...
Eligibility Criteria
Inclusion
- Female
- 45 to 60 years of age, inclusive
- At least 2 years since last menstrual cycle
- Intact uterus (womb).
Exclusion
- Existing fracture of the spine.
- Bone disorders, other than low bone mass
- History of cancer in the last 5 years. Also, any history, at any time, of breast cancer or cancer of the lining of the uterus.
- Abnormal or unexplained vaginal bleeding.
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00085956
Start Date
April 1 2004
End Date
February 1 2007
Last Update
March 9 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Diego, California, United States, 92103